[PTLA] Portola Pharmaceuticals, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For PTLA
PTLA is in the medium-term down -13% below S&P in 5 months. In the long-term down -39% below S&P in 3 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -2.28% | Sales Growth - Q/Q | -2.2% | P/E | ||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -31.53% | ROE | -36.59% | ROI | ||
| Current Ratio | 9.89 | Quick Ratio | Long Term Debt/Equity | Debt Ratio | 0.1 | ||
| Gross Margin | Operating Margin | -1592.24% | Net Profit Margin | -1595.01% | Dividend Payout Ratio | ||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | 113.04 M | Cash From Investing Activities | 9.44 M | Cash From Operating Activities | -47.15 M | Gross Profit | |
| Net Profit | -46.91 M | Operating Profit | -46.5 M | Total Assets | 486.3 M | Total Current Assets | 403.45 M |
| Total Current Liabilities | 40.79 M | Total Debt | Total Liabilities | 67.32 M | Total Revenue | 2.36 M |
Technical Data
| High 52 week | 37.76 | Low 52 week | 15.46 | Last close | 30.94 | Last change | 1.91% |
| RSI | 68.73 | Average true range | 1.39 | Beta | 1.71 | Volume | 8.33 M |
| Simple moving average 20 days | 15.82% | Simple moving average 50 days | 15.78% | Simple moving average 200 days | 14.08% |
Performance Data
| Performance Week | 24.76% | Performance Month | 18.27% | Performance Quart | -2.7% | Performance Half | 8.41% |
| Performance Year | -17.97% | Performance Year-to-date | 58.5% | Volatility daily | 3.23% | Volatility weekly | 7.23% |
| Volatility monthly | 14.81% | Volatility yearly | 51.32% | Relative Volume | 1513.75% | Average Volume | 1.04 M |
| New High | New Low |
News
2019-08-22 08:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2019-08-16 11:08:39 | Here's Why Portola Pharmaceuticals NASDAQ:PTLA Can Afford Some Debt
2019-08-13 19:32:00 | Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2019-08-13 07:25:15 | The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
2019-08-12 16:43:00 | Portola Pharmaceuticals Announces Proposed Offering of Common Stock
2019-08-08 16:15:00 | Why Portola Pharmaceuticals Is Rocketing 10.9% Higher Today
2019-08-08 01:31:18 | Edited Transcript of PTLA earnings conference call or presentation 7-Aug-19 8:30pm GMT
2019-08-07 21:24:06 | Portola Pharmaceuticals Inc PTLA Q2 2019 Earnings Call Transcript
2019-08-07 18:25:10 | Portola Pharmaceuticals PTLA Reports Q2 Loss, Tops Revenue Estimates
2019-08-07 16:05:00 | Portola Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
2019-08-07 11:20:03 | Bausch BHC Misses on Q2 Earnings & Sales, Raises View
2019-08-07 11:15:03 | Endo ENDP Q2 Earnings & Revenues Beat Estimates, Down Y/Y
2019-08-07 08:42:12 | Zoetis ZTS Looks Good: Stock Adds 7.6% in Session
2019-08-06 10:51:02 | Zoetis ZTS Beats on Earnings in Q2, Lifts 2019 Guidance
2019-08-06 08:30:00 | Portola Launches European Sales of Ondexxya® Andexanet Alfa with First Orders in Europe
2019-08-05 07:00:00 | U.S. Centers for Medicare and Medicaid Services CMS Increases New Technology Add-On Payment NTAP Reimbursement for Portola Pharmaceuticals' Andexxa
2019-07-31 10:36:02 | Portola Pharmaceuticals PTLA May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2019-07-17 08:30:00 | Portola Pharmaceuticals to Announce Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
2019-06-19 11:05:00 | Portola Presents New Interim Data on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
2019-06-18 08:04:49 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-06-13 08:03:31 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-06-11 08:04:20 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-06-10 08:02:23 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-06-08 08:09:16 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-06-04 08:04:30 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-05-28 16:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2019-05-24 09:00:17 | What’s Portola’s Growth Strategy for Fiscal 2019?
2019-05-24 07:30:43 | How Is Portola’s Andexxa Placed in the First Quarter?
2019-05-22 10:45:00 | Portola Pharmaceuticals Announces New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Spontaneous Non-Traumatic Intracranial Hemorrhage
2019-05-09 08:16:00 | 3 Key Takeaways From Portola Pharmaceuticals' Quarterly Results
2019-05-08 22:18:13 | Edited Transcript of PTLA earnings conference call or presentation 8-May-19 12:30pm GMT
2019-05-08 14:23:45 | Portola Pharmaceuticals Inc PTLA Q1 2019 Earnings Call Transcript
2019-05-08 13:10:00 | Why Portola Pharmaceuticals Is Tumbling 14.5% Today
2019-05-08 09:25:01 | Portola Pharmaceuticals PTLA Reports Q1 Loss, Tops Revenue Estimates
2019-05-08 08:19:33 | Portola Pharmaceuticals: 1Q Earnings Snapshot
2019-05-08 08:01:00 | Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
2019-05-08 06:30:00 | Portola Pharmaceuticals, Inc. to Host Earnings Call
2019-05-07 08:06:01 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-05-02 14:39:49 | Did Hedge Funds Drop The Ball On Portola Pharmaceuticals Inc PTLA?
2019-05-01 10:32:02 | Portola Pharmaceuticals PTLA May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2019-04-26 14:00:47 | European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ andexanet alfa, the First and Only Antidote for the Reversal of Factor Xa Inhibitors
2019-04-24 08:30:00 | Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development
2019-04-17 16:15:00 | Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019
2019-04-12 12:01:00 | Portola Pharmaceuticals: Is It Still a Buy?
2019-04-09 10:48:23 | See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
2019-03-26 17:32:59 | Amid talk of buyout, Peninsula biotech zeroes in on its blood-thinner antidote
2019-03-25 09:19:13 | Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
2019-03-21 06:30:00 | HLS Therapeutics Announces Q4 and Year-End 2018 Financial Results
2019-03-20 17:00:00 | Portola Pharmaceuticals’ Co-Founder Dr. Charles Homcy Retires from the Company’s Board of Directors